LB Pharmaceuticals Inc Common Stock
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- LB Pharmaceuticals Inc (LBRX), a clinical-stage biopharmaceutical company founded in 2015 and headquartered at One Pennsylvania Plaza, Suite 1025, New York, New York, develops novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company builds a pipeline leveraging the broad therapeutic potential of its lead product candidate, LB-102, an oral small molecule and new chemical entity that is a methylated derivative of amisulpride, a second-generation antipsychotic approved in over 50 countries; LB-102 is Phase 3-ready for acute schizophrenia, having reported positive top-line Phase 2 results in January 2025 demonstrating a statistically significant change in the Positive and Negative Syndrome Scale score, completed Phase 1 for bipolar I depression, and advancing an investigational long-acting injectable (LAI) formulation. LB Pharmaceuticals operates in the biotechnology sector, targeting patients with severe psychiatric disorders through clinical trials conducted primarily in the United States. In September 2025, the company completed a landmark initial public offering on Nasdaq, raising $285 million to fund a Phase 3 trial for LB-102 in schizophrenia starting early 2026, a Phase 2 trial for bipolar depression, and further pipeline development, following prior private financing exceeding $120 million including a $75 million Series C round.
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
LB Pharmaceuticals to Participate in Upcoming June Investor Events
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
LB Pharmaceuticals Inc (LBRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia
LB Pharmaceuticals CEO Maps LB-102 Milestones, Says Pipeline Fully Funded Into Q2 2029
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 1-Year High – Here’s What Happened
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
LB Pharmaceuticals Inc’s Lock-Up Period Will Expire on March 10th (NASDAQ:LBRX)
LB Pharmaceuticals to Participate in Upcoming March Investor Events
LB Pharmaceuticals Inc’s (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
LB Pharmaceuticals Announces $100.0 Million Private Placement
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program